Investors Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Key Points

• Investors notably increased their activity in Recursion Pharmaceuticals, purchasing 69,699 call options, which is a 172% increase over the typical volume of 25,642 options.
• Insider Najat Khan sold 36,599 shares at an average price of $5.52, resulting in a total transaction of over $202,000, reducing their position in the company by 5.19%.
• Recursion Pharmaceuticals reported a revenue increase of 33.3% year-over-year, despite posting a quarterly EPS of ($0.41), missing analyst expectations.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw some unusual options trading activity on Wednesday. Stock investors bought 69,699 call options on the stock. This represents an increase of approximately 172% compared to the typical volume of 25,642 call options.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the sale, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. The trade was a 5.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 8.43% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. TD Waterhouse Canada Inc. boosted its position in shares of Recursion Pharmaceuticals by 64.1% during the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company's stock worth $29,000 after buying an additional 2,200 shares during the period. AlphaQuest LLC acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth about $36,000. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after acquiring an additional 2,026 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Recursion Pharmaceuticals by 97.2% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company's stock valued at $46,000 after acquiring an additional 4,446 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $51,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Up 16.9%

RXRX stock traded up $0.89 during trading hours on Wednesday, reaching $6.12. 68,553,960 shares of the stock were exchanged, compared to its average volume of 25,449,707. The firm's 50-day moving average is $5.07 and its 200-day moving average is $5.12. The company has a market cap of $2.65 billion, a price-to-earnings ratio of -3.43 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.Recursion Pharmaceuticals's revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.40) EPS. On average, equities research analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

RXRX has been the subject of several recent research reports. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, September 11th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $7.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.